This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
ASXL1/2 mutations and myeloid malignancies
Journal of Hematology & Oncology Open Access 06 September 2022
-
Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia
Cancer Cell International Open Access 09 October 2021
-
Thrombocytosis in children and adolescents—classification, diagnostic approach, and clinical management
Annals of Hematology Open Access 12 March 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Douet-Guilbert N, Laï JL, Basinko A, Gueganic N, Andrieux J, Pollet B et al. Fluorescence in situ hybridization characterization of ider(20q) in myelodysplastic syndrome. Br J Haematol 2008; 143: 716–720.
Gelsi-Boyer V, Trouplin V, Adélaïde J, Bonansea J, Cervera N, Carbuccia N et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788–800.
Gelsi-Boyer V, Trouplin V, Adélaïde J, Aceto N, Remy V, Pinson S et al. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer 2008; 8: 299–314.
Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A et al. Mutations of TET2 in myeloid malignancies. N Engl J Med 2009; 360: 2289–2301.
Tefferi A, Pardanani A, Lim K-H, Abdel-Wahab O, Lasho TL, Patel J et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23: 905–911.
Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KIT816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23: 900–904.
Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009 (in press).
Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009; 113: 6403–6410.
Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324: 930–935.
Bernard F, Gelsi-Boyer V, Murati A, Giraudier S, Trouplin V, Adélaïde J et al. Alterations of NFIA in chronic malignant myeloid diseases. Leukemia 2009; 23: 583–585.
Etienne A, Carbuccia N, Adélaïde J, Bekhouche I, Rémy V, Sohn C et al. Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. Cancer Genet Cytogenet 2007; 176: 80–88.
Bruchova H, Merkerova M, Prchal J . Aberrant expression of microRNA in polycythemia vera. Haematologica 2008; 93: 1009–1016.
Van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009; 41: 521–523.
Acknowledgements
This work was supported by Inserm, Institut Paoli-Calmettes and a grant from Association pour la Recherche contre le Cancer (AM, no 4929, 2008).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carbuccia, N., Murati, A., Trouplin, V. et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 23, 2183–2186 (2009). https://doi.org/10.1038/leu.2009.141
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.141
This article is cited by
-
Clonal Hematopoiesis of Indeterminate Potential: Current Understanding and Future Directions
Current Oncology Reports (2023)
-
Epigenetic regulation by ASXL1 in myeloid malignancies
International Journal of Hematology (2023)
-
ASXL1/2 mutations and myeloid malignancies
Journal of Hematology & Oncology (2022)
-
Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data
Nature Medicine (2022)
-
Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations
Investigational New Drugs (2022)